Literature DB >> 11868804

Treatment patterns among newly diagnosed heart failure patients in general practice.

Saga Johansson1, Mari-Ann Wallander, Ana Ruigómez, RodríguezLuisAlberto García.   

Abstract

AIM: To examine treatment patterns of heart failure (HF) in general practice and to evaluate factors influencing the choice of that treatment, such as age, sex, severity of disease and co-morbidity.
METHODS: We used previously identified and confirmed incident cases of HF (patients aged 40-84 years) from the General Practice Research Database in the UK (n = 938). We collected recorded information on demographics. co-morbidity and drug treatment prescribed 1 year before and after the incident diagnosis in 1996.
RESULTS: Most of the study cohort was over 60 years old and presented with several concomitant diseases. Use of most cardiovascular drugs significantly increased after the diagnosis of HF. There was a greater than threefold increase in the use of angiotensin-converting enzyme inhibitors, while use of nitrates decreased after diagnosis of HF among men. Use of beta-blockers and calcium channel blockers slightly decreased after diagnosis.
CONCLUSION: We found that well-established treatment practices were followed by general practitioners. Severity of the disease favoured use of diuretics and a previous ischaemic heart disease and hypertension favoured use of beta-blockers and aspirin. Women and elderly patients were less likely to receive treatment with angiotensin-converting enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11868804     DOI: 10.1007/s00228-001-0397-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

Review 1.  The general practice research database: role in pharmacovigilance.

Authors:  Louise Wood; Carlos Martinez
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study.

Authors:  Willeke N Kasje; Petra Denig; Roy E Stewart; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Eur J Clin Pharmacol       Date:  2005-03-11       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.